
Zolivan™ Capsules (Itraconazole 100 mg / 200 mg Capsules)
Zolivan™ Capsules, available in 100 mg and 200 mg strengths, contain Itraconazole, an antifungal medication widely known for its effectiveness in treating systemic and localized fungal infections. Itraconazole works by disrupting the fungal cell membrane, thereby inhibiting fungal growth and preventing the spread of infection. This targeted action makes Zolivan™ a dependable choice for various fungal conditions affecting skin, nails, and internal systems.
Description
Key Benefits:
Broad-Spectrum Antifungal: Effectively combats a variety of fungal infections, including skin, nail, and systemic infections.
Potent and Targeted Action: Delivers strong results by inhibiting fungal cell membrane synthesis.
Convenient Dosage Options: Available in 100 mg and 200 mg strengths for tailored treatment based on individual needs.
Indications:
Treatment of dermatophyte infections, onychomycosis (nail infections), and systemic mycoses
Effective against conditions like candidiasis, aspergillosis, and histoplasmosis
Ideal for both acute and chronic fungal infections
Usage Instructions:
Zolivan™ Capsules should be taken as directed by a healthcare provider, generally with food to enhance absorption. Dosage and duration depend on the severity and type of infection.
Precautions:
Avoid use if allergic to Itraconazole or other azole antifungals.
Not recommended for individuals with liver or heart conditions unless advised by a physician.
Discuss with a healthcare provider if pregnant, breastfeeding, or taking other medications to prevent potential interactions.
Packaging:
Available in convenient blister packs for safe and easy dosing in both 100 mg and 200 mg capsules.
Zolivan™ Capsules provide a potent and reliable treatment for fungal infections, offering fast relief and effective management for improved well-being.
Reviews
There are no reviews yet.